[Skip to Content]
[Skip to Content Landing]
Other Articles
December 17, 1955


Author Affiliations

Bethesda, Md.

From the National Institute of Arthritis and Metabolic Diseases, National Institutes of Health. Dr. Bollet is now at Wayne University College of Medicine, Detroit.

JAMA. 1955;159(16):1501-1507. doi:10.1001/jama.1955.02960330001001

Prednisone and prednisolone have been found to be approximately four times as potent as cortisone and hydrocortisone in suppressing the inflammatory manifestations of rheumatoid arthritis.1 Since administration of these two synthetic steroids in moderate doses does not cause sodium retention or edema, they offer important advantages over previously used steroids. Cortisone and hydrocortisone have been employed in the treatment of systemic lupus erythematosus with considerable effectiveness in controlling many of the manifestations of this disease. These drugs, however, tend to intensify fluid retention and hypertension in patients with renal and cardiac involvement. It was thought advisable, therefore, to compare the relative merits of prednisone and prednisolone with the older steroids in the treatment of systemic lupus erythematosus and to determine the effectiveness and limitations of the newer steroids.

MATERIAL AND METHODS  This series consists of 10 patients with systemic lupus erythematosus whose disease had not been satisfactorily controlled at

First Page Preview View Large
First page PDF preview
First page PDF preview